We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
By Neil Maclucas
ZURICH--Novartis AG (NVS) said Tuesday its Signifor injectable drug has received U.S. regulatory approval for treating patients with a life-threatening hormonal disorder.
Basel-based Novartis said the U.S. Food and Drug Administration had approved long-acting-release Signifor for use in treating acromegaly patients who have either failed to respond to surgery, or for whom surgery isn't an option. The approval comes after two late-stage studies demonstrated the drug provided better disease control than existing therapies.
Acromegaly is a rare disorder caused by the over production of growth hormones, often originating from a benign tumor on the pituitary gland. Roughly 60 in one million people are estimated to develop acromegaly.
Novartis last month received Signifor approval from European regulators for treating the same hormonal disorder.
Write to neil.maclucas@wsj.com
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012005267
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US66987V1098
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
